Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East
Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East
复制标题
DOI：
10.1177/1078155220910209
复制
发表时间：
2020-03-17
影响因子：
1.3
通讯作者：
Riechelmann, Rachel
中科院分区：
文献类型：
--
作者：
Moghaddas, Azadeh;Adib-Majlesi, Mohammad;Riechelmann, Rachel
实体瘤患者使用广泛的细胞毒性药物。在这项研究中，我们的目的是检测、记录和描述性分析中东转诊肿瘤学-血液学大学附属医院住院实体瘤患者中潜在的药物相互作用。材料和方法在这项横断面研究中，实体瘤患者的病历被收治到伊朗伊斯法罕的转诊肿瘤中心在这六个月（2018年）的时间里，我们纳入了所有同时接受至少两种化疗或非化疗药物的患者。化疗和非化疗药物之间的潜在药物相互作用进行了评估与Lexi互动版本。1.1在线software.ResultsDuring研究期间，共招募了141例癌症患者，他们的药物治疗方案进行了彻底的分析。我们在纳入的患者中检测到227例中度或重度药物相互作用，其中96、71、32和28例相互作用分别属于C、D、B和X类别。114例患者（80.8%）在住院期间至少发生了一次潜在的药物相互作用。在机制上，大多数药物-药物相互作用（56.4%）是药效学。格拉司琼与甲氧氯普胺的相互作用居前10位（11.4%）。多西他赛和卡铂之间的相互作用是最常见的药物之间的相互作用肿瘤药物（总药物相互作用的2.6%）。ConclusionPotentially中度或重大药物相互作用经常发生在实体瘤的癌症患者之间，需要建立一个临床药学服务提供相关的药物治疗咨询，以防止这种潜在的严重问题。
IntroductionPatients suffering from solid tumors use a wide range of cytotoxic drugs. In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital.Materials and methodsIn this cross-sectional study, the medical record of solid tumor's patients who were admitted to the referral oncological center in Isfahan, Iran, during the six months period (2018) were considered. We included all patients who had received at least two chemotherapy or nonchemotherapy drugs simultaneously. The potential drug-drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver.1.1 online software.ResultsDuring the study period, a total of 141 cancer patients were recruited, and their drug therapy regiment was thoroughly analyzed. We detected 227 drug-drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively. One hundred and fourteen patients (80.8%) encountered at least one potential drug-drug interactions during their hospitalization. Mechanistically, most of drug-drug interactions (56.4%) were pharmacodynamics. Interaction between granisetron and metoclopramide were the top 10 detected interaction (11.4%). The interaction between docetaxel and carboplatin was the most frequent drug-drug interactions between oncology drugs (2.6% of total drug-drug interactions).ConclusionPotentially moderate or major drug-drug interactions frequently occur among solid tumor's cancer patients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern.